Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226156 | 1.00 | HDAC1 (0.44) | HDAC1HDAC2KDM1AMAOAHDAC3 | |
| SCHEMBL2638700 | 0.89 | HDAC1 (0.44) | HDAC1HDAC2KDM1AMAOAHDAC3 | |
| SCHEMBL3225718 | 0.89 | HDAC1 (0.44) | HDAC1HDAC2KDM1AMAOAHDAC3 | |
| SCHEMBL3225704 | 0.89 | HDAC1 (0.44) | HDAC1HDAC2KDM1AMAOAHDAC3 | |
| SCHEMBL2638696 | 0.89 | HDAC1 (0.44) | HDAC1HDAC2KDM1AMAOAHDAC3 | |
| SCHEMBL13458174 | 0.89 | HDAC1 (0.42) | HDAC1HDAC2HDAC3HDAC6 | |
| SCHEMBL10039321 | 0.89 | HDAC1 (0.41) | HDAC1HDAC2HDAC3HDAC6 | |
| SCHEMBL13458756 | 0.81 | HDAC1 (0.45) | HDAC1HDAC2KDM1AMAOAHDAC3 | |
| SCHEMBL10039309 | 0.79 | HDAC1 (0.44) | HDAC1HDAC2KDM1AMAOAHDAC3 | |
| SCHEMBL10039313 | 0.79 | HDAC1 (0.47) | HDAC1HDAC2KDM1AMAOAHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | IL4I1, MKI67, ABL1 | HDAC1 730/4885HDAC2 1799/4885KDM1A 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.